American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Merck KGaA (ETR: MRCG) strengthened its full-year 2025 outlook after posting higher third-quarter earnings, supported by strong momentum in its Healthcare and Life Science divisions despite ongoing softness in the Electronics segment. The German science and technology company now expects net sales between €20.8 billion and €21.4 billion and EBITDA pre of €6 billion to €6.2 billion, reflecting organic growth of 3% and 5–7%, respectively.
The updated forecast also factors in portfolio changes, including the July 2025 acquisition of SpringWorks Therapeutics and the divestment of the Surface Solutions business. Merck projects earnings per share pre of €8.20 to €8.60, based on a 22% tax rate, and anticipates operating cash flow between €3.6 billion and €4 billion.
Merck said organic sales growth will be led primarily by its Life Science and Healthcare sectors, with Electronics expected to decline. Within Healthcare, the company foresees continued strength from its Cardiovascular, Metabolism & Endocrinology franchise. Meanwhile, multiple sclerosis treatment Mavenclad is set to remain a growth driver, although its contribution may soften after a recent U.S. court ruling that enables competing products.
In the third quarter, Merck’s net sales rose 1% to €5.32 billion, while EBIT increased 11.3% to €1.22 billion, lifting the margin to 23%. EBITDA pre climbed 3.1% to €1.67 billion, and profit after tax advanced 10.6% to €898 million. These gains were supported by divestment-related income, including a €113 million disposal gain from the Surface Solutions sale and proceeds from a $175 million FDA priority review voucher transaction.
Healthcare sales reached €2.2 billion, driven by strong performances from Mavenclad and oncology therapy Erbitux. Life Science revenue increased to €2.24 billion, supported by robust demand in Process Solutions. Electronics revenue declined 5.2% to €875 million following the divestment.
Merck ended the quarter with €1.52 billion in operating cash flow and net financial debt of €9.29 billion, reflecting new bond issuances and the SpringWorks acquisition. The company expects 2025 to remain volatile due to macroeconomic and currency factors, with the euro–U.S. dollar exchange rate likely staying between 1.11 and 1.15.
